32results about How to "Reduces symptom" patented technology

Provided herein are compositions comprising non-human animals comprising neurons expressing stabilized step function opsin proteins on neural plasma membranes and methods of using the same to selectively depolarize neurons residing in microcircuits of the pre-frontal cortex to affect one or more social behaviors, communications, and / or conditioned behaviors in the non-human animal.

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.

The subject invention provides materials and methods for treating allergy in animals. In a preferred embodiment, the invention provides methods for alleviating an animal's hypersensitive response to allergens, including, without limitation, migraine, asthma, allergic rhinitis, digestive disturbances, coeliac disease, conjunctivitis, urticaria, eczema, drowsiness, hyperactivity (in children), tinnitus, recurrent sinusitis and ear infections. Specifically exemplified herein is the use of a cysteamine compound to reduce the hypersensitive response in animals to allergens. In a preferred embodiment, oral administration of cysteamine hydrochloride to an animal diagnosed with an allergy can substantially reduce the animal's reaction to the allergen.

Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and an alpha2delta ligand and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

A system and method for use in moderating symptoms associated with vestibular disorders. The patient stands atop a balance platform and balances or performs other exercises on the platform. The exercises require the patient to work against the instability of an inflatable bladder positioned beneath the balance platform. Training difficult may be increased or decreased by changing the pressure of the inflatable bladder. Increased pressure makes the bladder firm, which is easier to balance upon and decreased pressure softens the bladder, making it more difficult to balance upon. Over time, the repeated performance of the exercise sessions improves the impairment the patient is experiencing due to the symptoms of the vestibular disorder.

The present invention relates to a single phase temperature management composition. The composition includes from 0.01% to 10% by weight of a neurosensory agent and from 0.01% to 30% by weight of an antiperspirant component. The composition also includes a polar carrier where the polar carrier includes water and monohydric alcohol. The ratio of water to monohydric alcohol ranges from 0.0625:1 to 1.5:1. The compositions of the invention have a viscosity at room temperature of less than 2500 centipoise.

Compositions and methods for reducing hangover symptoms. Generally, a hangover reducing composition includes one or more plant extracts, such as prickly pear cactus extract, white willow bark extract, milk thistle extract, green tea extract, and combinations thereof. In some cases, the composition further includes supplemental nutrients, such as vitamins and minerals (including electrolytes). Some examples of suitable nutrients include sodium, potassium, magnesium, and vitamins C, B1, B2, B3, B6, and B12. The composition is administered to a person in any suitable form, including as a carbonated soft drink, an energy drink, a tea, a sports drink, a non-carbonated drink, a pill, an elixir, and so forth. In some preferred instances, the composition is formulated as a carbonated soft drink. In order to reduce hangover symptoms, the composition is ingested before, during, and / or after the consumption of a drug, such as alcohol.

The present invention is directed to methods and compositions for making and using a new polymorph of cinacalcet hydrochloride.

Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic.

Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and / or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and / or TMAO sequestering agent.

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.

A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.

External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations may be administered via inhalation, injection, or orally. The formulations may be in the form of an ointment, lotion, cream, gel, drop, suppository, spray, liquid, powder, granule, solution, suspension, capsule, or tablet. Methods of treating inflammatory or related diseases by administering an effective amount of an EGS in a pharmaceutically acceptable carrier are also described. In preferred embodiments, the disease is asthma, allergic rhinitis, food allergies, atopic skin disease such as eczema, IL-4 and / or IL-13 dependent malignancies, IL-4 and / or IL-13 dependent autoimmune diseases, atopic diseases, the flu, and diseases caused by IL-4 dependent replication of viruses.

The present invention relates to the use of one or more expression vectors comprising certain nucleic acid sequences encoding a combination of NPY and / or one or more of its receptors (Y1, Y2, Y4, Y5, y6), and / or galanin and / or one or more of its receptors (GALR1, GALR2, GALR3), and / or somatostatin and / or one or more of its receptors (SST1, SST2, SST3, SST4, SST5), in the preparation of a medicament for treatment of a disorder of the nervous system, such as a neurological or a psychiatric disease chosen from epilepsy, depression, and anxiety. The invention further relates to vectors that comprise nucleic acid sequences encoding the above combination, to compositions comprising such vectors and to a method of delivery and expression of the above combination of nucleic acid sequences into cells of the nervous system to treat neurological or psychiatric diseases in humans or animals.

Formulations for transdermal pharmaceutical compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transdermal permeation enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Transdermal pharmaceutical compositions include liquid dosage forms, such as, for example solutions, liquid sprays, lotions, and the like. Additionally, transdermal pharmaceutical compositions include semi-solid dosage forms, such as, for example emulsions, creams, gels, pastes, ointments, and the like. Transdermal pharmaceutical compositions will deliver testosterone and AI through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of testosterone and AI. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol.

Disclosed is a method of treatment for alleviating pain and other problems associated with digestive disorders in general and Irritable Bowel Syndrome in particular using glycerin fatty acid esters such as medium and long chain glycerides.

Compositions useful for the treatment of hyperproliferative dermal diseases of the scalp. Specifically, topical gel and liquid compositions that include calcipotriol and nicotinamide in a polyethylene glycol-based carrier, for topical application to the scalp.

Provided herein are cysteamine or a pharmaceutically acceptable salt thereof and methods of using such for treating asthma (e.g., moderate to severe persistent asthma) or reducing the risk of asthma occurrence.

Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.

Methods and formulations for the treatment of multiple sclerosis with drugs with affinity for both serotonergic 5-HT2 and dopaminergic receptors such as the D2 receptor are herein disclosed. According to one embodiment, a method includes delivering a therapeutic dosage of drugs with affinity for both serotonergic 5-HT2 and dopaminergic receptors such as the D2 receptors to a subject exhibiting symptoms of multiple sclerosis to alleviate the symptoms.

A clogged duct massager includes a handle, a pair of arms each affixed at. a lower end to an upper end of the handle, and a massage roller having opposing sides that rotatably connect to the upper end of each arm, such that the massage roller is freely rotatable between the pair of arms. A power supply disposed within the handle is operably connected to a heating element and a vibration motor disposed within the massage roller. Temperature and vibration controls disposed on the handle allow the user to selectively activate or deactivate the heating element and the vibration motor. The massage roller pressure, heat, and vibration can be applied to any desired area of the skin in order to prevent and alleviate clogging of ducts and pores, thereby helping to prevent mastitis and other negative conditions associated with dogged ducts and pores.

The present invention provides neuroprotective preparations, specifically, Dunaliella alga preparations and uses thereof in the treatment and prophylaxis of neurodegenerative disorders, protein misfolding and cognitive decline.

Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem / progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem / progenitor cells. Pharmaceutical compositions relating to the methods are also described.

This invention relates to the treatment of Alzheimer's disease, the reduction of the progression of Alzheimer's disease, and the alleviation of symptoms of Alzheimer's disease by administering ApoA-1 Milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an rAAV vector encoding ApoA-1 Milano or an active fragment thereof, to a mammal having Alzheimer's disease or a symptom of Alzheimer's disease.

This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and / or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).

The present invention provides compositions and methods of using α2 adrenergic receptor agonists as treatments for ADHD. The α2 adrenergic receptor agonist for use with these methods is a benzimidazole derivative, and may be specifically N-(4,5-Dihydro-1H-imidazol-2-yl)-7-cyano-4-methyl-1H-benzimidazol-5-amine acetate. Formulations and routes of administration are also described.

The present invention relates to methods for identifying candidate therapeutics for a disease caused by a viral envelope protein. In particular, the method can include contacting a test envelope protein with the candidate and determining its activity.